Announcing an exciting, unique & customer-focused collaboration

We’re delighted to announce a new collaboration between HEMEX and The Bioinformatics CRO which will provide an even more complete CRO service for our start-ups! Find out how this collaboration can support you throughout your Clinical Development phase.

How can we make the Informed Consent Form process more patient-friendly?

Complicated words and sentences may be misunderstood and are very often unfamiliar to the patients. This led us to discuss how we could find the optimal solution for all parties involved in a clinical study: the patient, physician, and sponsor/CRO.

Comms&Media service for startups powered by Benz Advisory, mediacrewgroup, and HEMEX

Benz Advisory, mediacrewgroup, and HEMEX join forces to support early-stage companies with strategic communications through a new service called Comms&Media. Targeted at early-stage businesses from all industries, it offers a unique, holistic approach to help companies develop and implement effective external and internal communications.

How to bake a “delicious” pitch for investors?

Every Start-up knows the importance of a great pitch. Today we want to give you some advice on how to find out the essential ingredients to bake a delicious pitch which investors will enjoy every single bite. More importantly, leave them craving for more!

Resistell Announces Start Of Performance Evaluation Study

Resistell has started the Performance Evaluation Study (PES) of its groundbreaking nanomotion technology at Lausanne University Hospital. At HEMEX, are very happy to be part of this project, as we will be monitoring the clinical trial over the next 12 months.

A day to reimagine a better future for every child

The World Conference for the Well-being of Children in Geneva, Switzerland, proclaimed June 1 to be International Children’s Day in 1925. Currently is being celebrated on November 20 to commemorate the Declaration of Rights of the Child by the UN General Assembly. At HEMEX, we have decided this year to start early discussions about children’s rights and well-being.

Major milestone for Inura Medical, who closes pre-series A financing round

Inura Medical’s mission is to improve women’s health through the development of an urethral ovulum for the treatment of patients suffering from urinary bladder diseases. Their first pharmaceutical product is addressing an unmet medical need in overactive bladder (OAB). 

Our portfolio company HexagonFab secures CHF 2.5m seed funding

HexagonFab, a spin-out from the University of Cambridge, has developed a novel approach for drug discovery and production process monitoring called the Bolt. This innovative device is an analytical lab instrument that provides convenient and affordable access to molecular binding analytics.